TESARO (TSRO) PT Raised to $100 at Mizuho Ahead of Multiple Catalysts

Mizuho Securities analyst Eric Criscuolo reiterated a Buy rating and lifted his price target on Tesaro (NASDAQ: TSRO) to $100.00 (from $94.00) ahead of multiple catalysts with drivers in place.

Criscuolo commented, "We're reiterating our Buy and raising our PT to $100. We see a steady stream of potential data catalysts for niraparib over the next year-plus that could add to the excitement following NOVA results. VARUBI is gaining share, with a 1H17 IV launch to address the vast majority of the U.S. market, and an early immuno-oncology pipeline could produce first-in-class assets. Cash utilization is going up but its funding significant product launches. TSRO remains our top Biotech pick."

For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.

Shares of Tesaro closed at $89.45 yesterday.

You May Also Be Interested In

• Tyler Tech (TYL) PT Raised to $500 at Oppenheimer
• Teradyne (TER) PT Raised to $125 at TD Cowen
• Merck (MRK) PT Raised to $143 at Truist Securities